Clinical relevance of pretransplant HLA Class II Donor-specific antibodies in renal transplantation patients with negative t-cell cytotoxicity crossmatches

Annals of Laboratory Medicine

Volumn 32, Issue 2, 2012, Pages 139-144

  Song, Eun Young ^a   Lee, Yu Joo ^a   Hyun, Jungwon ^a   Kim, Yon Su ^a   Ahn, Curie ^a   Ha, Jongwon ^a   Kim, Sang Joon ^a   Park, Myoung Hee ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Antibody mediated rejection; Donor specific hla antibodies; Renal transplantation

Indexed keywords

EID: 84859202982     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2012.32.2.139     Document Type: Article

References (21)

1. Gebel HM and Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation 2000;69:1370-4. (Pubitemid 30238726)
2. Pei R, Lee JH, Shih NJ, Chen M, Terasaki Pl.Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003;75:43-9. (Pubitemid 36139693)
3. Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, et al. Clinical relevance ofpreformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008;8:324-31.
4. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance ofpretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009;87:1681-8.
5. Eng HS, Bennett G, Tsiopelas E, Lake M, Humphreys I, Chang SH, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008;8: 2335-42.
6. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies incytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation 2008;85: 1200-4. (Pubitemid 351590199)
7. Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels ofhuman leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009;70:580-3.
8. Vlad G, Ho EK, Vasilescu ER, Colovai Al, Stokes MB, Markowitz GS, et al. Relevance ofdifferent antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009;70:589-94.
9. Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010;10:582-9.
10. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010;21:1398-406.
11. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Nairn M, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008;86:820-5.
12. Vaidya S, Cooper TY, Avandsalehi J, Barnes T, Brooks K, Hymel P, et al. Improved flow cytometric detection of HLA alloantibodies using pronase: potential implications in renal transplantation. Transplantation 2001;71: 422-8. (Pubitemid 32175980)
13. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97working classification of renal allograft pathology. Kidney Int 1999;55:713-23. (Pubitemid 29082898)
14. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria -an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708-14. (Pubitemid 36745243)
15. Pollinger HS, Stegall MD, Gloor JM, Moore SB, Degoey SR, Ploeger NA, et al. Kidney transplantation inpatients with antibodies against donor HLA class II. Am J Transplant 2007;7:857-63. (Pubitemid 46481187)
16. Stastny P, Ring S, Lu C, Arenas J, Han M, Lavingia B. Role ofimmunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum Immunol 2009;70:600-4.
17. Issa N, Cosio FG, Gloor JM, Sethi S, Dean PG, Moore SB, et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class Il antibody levels. Transplantation 2008;86:681-5.
18. Jin YP, Fishbein MC, Said JW, Jindra PT, Rajalingam R, Rozengurt E, et al. Anti-HLA class Iantibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004;65:291-302. (Pubitemid 38543064)
19. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure tosub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004;34:2303-12. (Pubitemid 39256112)
20. Salama AD, Delikouras A, Pusey CD, Cook HT, Bhangal G, Lechler RI, et al. Transplant accommodation inhighly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001;1:260-9. (Pubitemid 33674170)
21. Warner PR, Youngs D, Nelson KA. HLA density on microparticles versus antibody detection sensitivity: implications for crossmatch prediction. Hum Immunol 2007;68(S):S28.